Ligand Pharmaceuticals LGND Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's net change in cash?
- Ligand Pharmaceuticals (LGND) reported net change in cash of -$59.83M in Q1 2026.
- How has Ligand Pharmaceuticals's net change in cash changed year-over-year?
- Ligand Pharmaceuticals's net change in cash decreased by 146.0% year-over-year, from -$24.32M to -$59.83M.
- What is the long-term trend for Ligand Pharmaceuticals's net change in cash?
- Over 3 years (2021 to 2025), Ligand Pharmaceuticals's net change in cash has grown at a 50.9% compound annual growth rate (CAGR), from -$29.86M to $102.62M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.